真人做爰48姿势视图片|少妇真人直播免费视频|日本真人做爰A片|真人裸体做爰视频|真人与拘做爰视频免费观看|真人与拘做受免费视频一

尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白

Active Plasminogen Activator, Urokinase Receptor (uPAR)

CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3

  • 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 產(chǎn)品包裝(模擬)
  • 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 產(chǎn)品包裝(模擬)
  • APA141Hu04.jpg Figure. SDS-PAGE
  • Certificate 通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

活性實驗

Urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored protein. Besides regulating proteolysis, uPAR could also activate many intracellular signaling pathways that promote cell motility, invasion, proliferation and survival through cooperating with transmembrane receptors. uPAR is overexpressed across a variety of tumors and is associated with cancer invasion and metastasis. ITGb1 has been identified as an interactor of uPAR, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human uPAR and recombinant human ITGb1. Briefly, uPAR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to ITGb1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-uPAR pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human uPAR and recombinant human ITGb1 was shown in Figure 1, the EC50?for this effect is 0.165 ug/mL.

用法

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

儲存

避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。

相關(guān)產(chǎn)品

編號 適用物種:Homo sapiens (Human,人) 應(yīng)用(僅供研究使用,不用于臨床診斷!)
RPA141Hu01 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA141Hu02 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APA141Hu04 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 Cell?culture;?Activity?Assays.
RPA141Hu04 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA141Hu03 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA141Hu04 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 WB
PAA141Hu01 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 WB; IHC; ICC; IP.
PAA141Hu02 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 WB; IHC; ICC; IP.
PAA141Hu03 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 WB; IHC; ICC; IP.
LAA141Hu71 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
LAA141Hu83 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
LAA141Hu81 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
FAA141Hu81 抗尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) FCM
MAA141Hu22 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 WB; IHC; ICC; IP.
MAA141Hu21 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體 WB; IHC; ICC; IP.
LAA141Hu82 尿激酶型纖溶酶原激活因子受體(uPAR)單克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
SEA141Hu 尿激酶型纖溶酶原激活因子受體(uPAR)檢測試劑盒(酶聯(lián)免疫吸附試驗法) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA141Hu 尿激酶型纖溶酶原激活因子受體(uPAR)等多因子檢測試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.

參考文獻

雜志 參考文獻
International Journal of Cancer Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice [Wiley: source]
Biomark Insights Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism [PubMed: PMC3623607]
Biomarker insights Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD) [PubMed: PMC3762604]
Am J Emerg Med Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis [PubMed: 26615223]
Archives of Clinical Infectious Diseases Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis [Archcid: 26346]
The American Journal of Emergency Medicine Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis [science:S0735675715009559]
Journal of Clinical and Experimental Hepatology Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD)?… [10.1016:j.jceh.2018.02.001]
Turkish journal of trauma & emergency surgery The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis [Pubmed: 31475329]
CELL TRANSPLANTATION Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction [33787356]
留言咨詢
平湖市| 融水| 四会市| 乌审旗| 鹤庆县| 聂拉木县| 屏山县| 岚皋县| 舒城县| 尉氏县| 县级市| 离岛区| 甘谷县| 遂川县| 峨边| 万载县| 江孜县| 嘉祥县| 灵寿县| 炎陵县| 共和县| 灌云县| 黔西县| 宁化县| 黄梅县| 雅安市| 蒙山县| 高邮市| 灯塔市| 穆棱市| 常州市| 慈溪市| 承德市| 襄垣县| 墨脱县| 明溪县| 遵义市| 南陵县| 沛县| 榕江县| 光泽县|